BDTX Projected Dividend Yield

Black Diamond Therapeutics Inc ( NASDAQ : BDTX )

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies targeting oncogenic mutations. These therapies aim to serve broad genetically defined patient populations, overcome resistance, reduce wild-type toxicities, and penetrate the brain for central nervous system (CNS) diseases. They are advancing two programs: BDTX-1535, an EGFR MasterKey inhibitor for EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a RAF MasterKey inhibitor for KRAS, NRAS, and BRAF alterations in solid tumors. They also have BDTX-4876, targeting FGFR2/3 mutations, and another candidate targeting an undisclosed oncogene.

21 YEAR PERFORMANCE RESULTS